SCHEMBL7628660

SCHEMBL7628660

CCn1c(N2CCCN(C(=O)OC(C)(C)C)CC2)nc2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
NPSR1 Q6W5P4 2/20 0.56
MAPT P10636 4/20 0.56
LMNA P02545 3/20 0.56
KMT2A Q03164 2/20 0.55
MEN1 O00255 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2C19 P33261 1/20 0.55
KCNH2 Q12809 1/20 0.55
CKS1B P61024 1/20 0.53
SKP1 P63208 1/20 0.53
SKP2 Q13309 1/20 0.53
GAA P10253 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
POLB P06746 1/20 0.50
OPRM1 P35372 1/20 0.49
OPRD1 P41143 1/20 0.49
OGFRL1 Q5TC84 1/20 0.49
ALOX15 P16050 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6595306 0.90 ALDH1A1 (0.57) ALDH1A1NPSR1CKS1BSKP1SKP2
SCHEMBL6592173 0.89 ALDH1A1 (0.59) ALDH1A1NPSR1POLB
SCHEMBL7626255 0.89 ALDH1A1 (0.51) ALDH1A1NPSR1MAPTLMNAKMT2A
SCHEMBL7620342 0.88 OPRM1 (0.51) ALDH1A1NPSR1MAPTLMNAKCNH2
SCHEMBL7627768 0.88 ALDH1A1 (0.55) ALDH1A1NPSR1POLBOPRM1OPRD1
SCHEMBL6596284 0.88 HTR3A (0.53) ALDH1A1NPSR1MAPTLMNAKMT2A
SCHEMBL7487632 0.86 ALDH1A1 (0.53) ALDH1A1NPSR1CKS1BSKP1SKP2
SCHEMBL7621503 0.86 ALDH1A1 (0.53) ALDH1A1NPSR1CKS1BSKP1SKP2
SCHEMBL6595962 0.86 HTR3A (0.56) KMT2AMEN1CYP1A2CYP3A4CYP2C19
SCHEMBL6595821 0.86 ALDH1A1 (0.52) ALDH1A1NPSR1CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6423704-B2 CROHN'S DISEAS, ANTIULCER AGENTS, ASTHMA, EMESIS AVENTIS PHARMACEUTICALS INC. 2002-07-23 US disclosed
US-20010034343-A1 Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases AVENTIS PHARMACEUTICALS INC. 2001-10-25 US disclosed
US-6194406-B1 HISTAMINE RECEPTOR ANTAGONISTS; TACHYKININ RECEPTOR ANTAGONISTS; ASTHMA; BRONCHITIS; INFLAMMATORY BOWEL DISEASES, INCLUDING CROHN'S DISEASE AND ULCERATIVE COLITIS; SEASONAL RHINITIS; SINUSITIS; ANTIALLERGENS; EMETIC AGENTS AVENTIS PHARMACEUTICALS INC. 2001-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034343-A1 Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases HRH4, HRH2, HRH1 ALDH1A1 953/4885NPSR1 102/4885MAPT 3666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.